We are live on !
Find out more
Eventide Asset Management Portfolio holdings
AUM
$7.48B
Turnover
27.68%
1-Year Est. Return
104.76%
This Fund
S&P 500
This Quarter Est. Return
+18.78%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$5.71B
AUM Growth
+$688M
(+14%)
Cap. Flow
-$39.8M
Cap. Flow % of AUM
Cap. Flow %
-0.7%
Top 10 Holdings %
Top 10 Hldgs %
24.42%
Holding
257
New
40
Increased
127
Reduced
58
Closed
20
Avg Time Held
1.7
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EQT Corp
EQT
|
+$26.6M |
| 2 |
Chewy
CHWY
|
+$26M |
| 3 |
Verisk Analytics
VRSK
|
+$25.3M |
| 4 |
Frontdoor
FTDR
|
+$24.3M |
| 5 |
Lam Research
LRCX
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celldex Therapeutics
CLDX
|
+$46.7M |
| 2 |
Micron Technology
MU
|
+$33.6M |
| 3 |
Snowflake
SNOW
|
+$29.5M |
| 4 |
Inspire Medical Systems
INSP
|
+$21.7M |
| 5 |
Evolent Health
EVH
|
+$18.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.06% |
| 2 | Technology | 18.81% |
| 3 | Industrials | 18.23% |
| 4 | Consumer Discretionary | 7.44% |
| 5 | Utilities | 4.58% |
Similar funds
Eventide Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Eventide Asset Management held 257 positions worth $5.71B, up 14% from $5.02B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Eventide Asset Management's Q2 2025 filing shows 40 new, 127 increased, 58 reduced and 20 closed positions. Its largest new stake was Frontdoor: 483,677 shares worth $28.5M. The largest sale was Celldex Therapeutics, an estimated $46.7M.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q2 2025 buy was Frontdoor: 483,677 shares worth $28.5M.
- Eventide Asset Management added most to EQT Corp in Q2 2025, an estimated $26.6M increase.
- Eventide Asset Management's biggest Q2 2025 reduction was Celldex Therapeutics, cutting an estimated $46.7M.
- Eventide Asset Management fully exited Krystal Biotech in Q2 2025, selling an estimated $17.3M.
- Eventide Asset Management's ten largest holdings make up 24% of its $5.71B portfolio in Q2 2025.
- Eventide Asset Management opened 40 new positions and closed 20 in Q2 2025.
- Eventide Asset Management's portfolio value rose 14% quarter-over-quarter to $5.71B.
Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.